New trials, publications, preprints and grants on this target, month by month.
Trial
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
31 Aug 2027· PHASE2 · RECRUITING· CTGOV
Trial
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
11 Nov 2026· PHASE1_PHASE2 · SUSPENDED· CTGOV
Publication
NRAS Mutations in Different Melanoma Histotypes: Molecular and Clinical Implications.
26 Oct 2026· Current oncology reports· PUBMED
Publication
Discovery and Synthesis of Selective Casein Kinase 1δ Degraders for Suppressing Oncogenic NRAS-Mutant Melanoma.
22 Oct 2026· Journal of medicinal chemistry· PUBMED
Publication
The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma.
8 Oct 2026· Leukemia research reports· PUBMED
Publication
Combined talimogene laherparepvec and binimetinib in NRAS-mutated melanoma induces anti-tumor immunity.
29 Sept 2026· The Journal of clinical investigation· PUBMED
Publication
Comment on 'Testing patterns, patient and tumour characteristics and survival by NRAS and KIT genotype in melanoma': can survival associations be inferred from selectively tested populations?
25 Sept 2026· Clinical and experimental dermatology· PUBMED
Publication
Histopathologic, Genomic, and Clinical Characteristics of Primary Cutaneous Melanocytic Tumors With Concomitant NRAS Q61 and IDH1 R132C Mutations.
8 Sept 2026· Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc· PUBMED
Publication
The association of NRAS and BRAF mutations with overall survival and surgical outcomes in stage IV colorectal cancer.
2 Sept 2026· Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract· PUBMED
Trial
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
14 Aug 2026· PHASE3 · RECRUITING· CTGOV
Publication
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma.
14 Aug 2026· Cancer research· PUBMED
Publication
NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib.
11 Aug 2026· Blood· PUBMED
Publication
Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma.
31 Jul 2026· Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie· PUBMED
Publication
Performance Evaluation of a Colorectal Cancer-Associated MassARRAY-Based Hotspot Genotyping Assay for KRAS, NRAS, BRAF, and PIK3CA Using Solid Tumor Specimens.
23 Jul 2026· Frontiers in bioscience (Landmark edition)· PUBMED
Publication
Structural basis for oligoclonal T cell recognition of a shared NRAS cancer neoantigen.
20 Jul 2026· Structure (London, England : 1993)· PUBMED
Publication
Sirolimus outperforms alpelisib in models of NRAS Q61R -driven vascular overgrowth.
13 Jul 2026· Blood vessels, thrombosis & hemostasis· PUBMED
Publication
Retraction notice to "Ultra-sensitive detection of melanoma NRAS mutant ctDNA based on programmable endonucleases" [Cancer Genetics 294-295 (2025) 47-56].
11 Jul 2026· Cancer genetics· PUBMED
Publication
Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.
23 Jun 2026· European journal of cancer (Oxford, England : 1990)· PUBMED
Publication
The Molecular Heterogeneity of NRAS Variants in Thyroid Nodules.
17 Jun 2026· Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery· PUBMED
Publication
KRAS/NRAS/BRAF Mutations and Mismatch Repair Deficiency in Patients with Early-Onset Colorectal Cancer: A Clinicopathological Analysis.
12 Jun 2026· International journal of surgical pathology· PUBMED
Publication
Durable Response to Sotorasib Plus Panitumumab in NRAS G12C-Mutated, Microsatellite Instability-High (MSI-H) Rectal Cancer Refractory to Immunotherapy.
7 Jun 2026· Cureus· PUBMED
Publication
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.
2 Jun 2026· Leukemia· PUBMED
Publication
Melanoma with Blue Nevus-like Morphology Harboring NRAS and NF1 Mutation.
17 May 2026· Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG· PUBMED
Publication
High yield production of C-terminally processed KRAS4a, HRAS, and NRAS for biophysical study.
15 May 2026· Protein expression and purification· PUBMED
Publication
Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma.
10 May 2026· Carbohydrate polymers· PUBMED
Publication
Recurrent primary hyperparathyroidism with ipsilateral multifocal papillary thyroid carcinoma of classical, warthin-like, and follicular variants harboring distinct BRAF and NRAS mutations: a rare case report.
9 May 2026· World journal of surgical oncology· PUBMED
Trial
A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
1 May 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Diacylglycerol Kinase Eta as a Novel Target in NRAS Mutant Melanoma.
1 May 2026· Pigment cell & melanoma research· PUBMED
Publication
Frequency and Prognostic Value of KRAS, NRAS, and BRAF Mutations in Metastatic Colorectal Cancer: An Iranian Cohort Study.
30 Apr 2026· Middle East journal of digestive diseases· PUBMED
Publication
Patterns of KRAS, NRAS, and BRAF mutations in colorectal cancer in Chile: a 3-year real-world evidence [2019-2021]-a brief report.
30 Apr 2026· Journal of gastrointestinal oncology· PUBMED